WSCCG Prescribing Data

Slides:

Advertisements

Similar presentations

VALUE IN RESPIRATORY PRESCRIBING Dr Vince Mak, Consultant Physician, NWLH Trust.

Advertisements

Improving Inhaler Technique through Community Pharmacy Service Greater Manchester Area Team January 2015.

Nottingham North and East Strategy Medicines Management 2014/15.

Nottingham West CCG Prescribing Team Beth Carney/ Dawn Gajree / David Sharpe September 2014.

Oxygen Ward Audits 2014 Linda Pearce Respiratory Consultant Nurse West Suffolk NHS Foundation Trust.

Improving Inhaler Technique through Community Pharmacy Service Greater Manchester Area Team Autumn 2014.

Respiratory Prescribing

Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.

Faculty Research Advisor: Dr. David Blake. Background Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and.

Trends in Usage of Non-Opioid Analgesics in General Practice in England © Copyright NHSBSA 2008.

VALUE AND RESPONSIBLE RESPIRATORY PRESCRIBING Dr Vince Mak, Consultant Physician, NWLH Trust.

Karen Homan NHS Bedfordshire

Trends in Spending on Selective Beta 2 Agonists in General Practice in England.

London Respiratory Team Understanding respiratory spend and increasing value: Inhalers and nicotine replacement therapy Responsible Respiratory Prescribing.

Medicines management update Catherine Butler Medicines Management Pharmacist.

CHP Respiratory meeting Welcome Dr Ninian Hewitt.

The Specials Trajectory Richard Jones, Head of Medicines Management Team & Accountable Officer for Controlled Drugs 8 th February /13/20151.

Trends in Spending on Selective Beta 2 Agonists in General Practice in England © Copyright NHSBSA 2009.

SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£

Delivering improvements in childhood asthma outcomes; A collaborative approach Dr Richard Iles 24 March 2015.

Responsible Respiratory Prescribing

Severe breathlessness

Automated Metered Dose Inhaler Presented By Group 11: Maria del Carmen Carrillo Jennifer B. Struble Loyrirk Temiyakarn.

MEDICINES OPTIMISATION IN DIABETES Yvonne Parker Medicines Optimisation Pharmacist Stoke-on-Trent CCG.

Berkshire West CCG TIPs 28th January 2015

Wendy Pigg Practice support Pharmacist/Independent Prescriber

Respiratory medication use in Australia 2003–2013: Treatment of asthma and COPD AIHW: Correll PK, Poulos LM, Ampon R, Reddel HK and Marks GB. Published.

Improving the experience of all Londoners with COPD and minimising the impact of the disease London Respiratory Team Medicines Management Workstream Dr.

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.

Lynn Helliwell.

Adherence and beliefs to medication/inhalers in patients with COPD

COPD The Why, The How, and The Where

Medicines Optimisation

Jessica E. Bates, Pharm.D. PGY-1 Pharmacy Resident

Respiratory Services Right Care Optimisation Workshop

Promotion of New Diabetes Products in the District of Columbia

Research where it is most needed National Respiratory Strategy

COPD PATHWAY AND PRESCRIBING POLICY IN LAMA options (stop SAMA):

Pedro Chorão, Ana M. Pereira, João A. Fonseca Respiratory Medicine

Medicines Management – COPD update for LPC Jyoti Saini Hema Patel

Pharmacy & Medicines Optimisation Team

Summary and Next Steps Linda Lord – Chief Pharmacist

Treatment Strategies in Mild to Moderate COPD

Antonio Anzueto, MD, Marc Miravitlles, MD CHEST

MUR and NMS Respiratory Toolkit.

Trimipramine – Summary of West Suffolk CCG and PrescQIPP Guidance

Medicines Optimisation

COPD Workshop for Prescribing Lead GPs Dr Firas Watfeh, Governing Body Member and Prescribing Lead GP.

COPD Placebo Inhaler Device Kit Linda Lord,Chief Pharmacist

An Interprofessional Approach to the Patient With Chronic Airway Disease.

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

Anticoagulants: System-Level Contracting

Prescribing What can we learn from this year to inform 16/17?

WSCCG Woundcare Prescribing Walé Abimbola Senior Pharmacist, WSCCG

Expert Input: Q&A and discussion

Childhood Asthma : Lessons still to be learnt

Lynn Orford Community Respiratory Team and HOSAR Lead

Antimicrobial Stewardship

Specific therapeutic and prophylactic interventions to consider in different taxonomic groups of chronic obstructive pulmonary diseases (COPDs). Specific.

Launch of new COPD guidelines

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Chronic Obstructive Pulmonary Disease

Nottinghamshire COPD and Asthma Guidelines

Prescribing Update - Respiratory July 2019

OTC – The prescribing picture for last year - Change in spend Jan 17 to Jan 18 Change from Jan 17 to Jan 18 LE – 13% reduction in spend LW – 9% reduction.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Priscilla A. Zetstra–van der Woude, MSc, J. Sebastiaan Vroegop, MD, H

Agenda. Diagnosis, Assessment, and Treatment of the COPD Patient in Primary Care.

Presentation transcript:

Inhalers currently prescribed in West Suffolk Linda Lord, Chief Pharmacist WSCCG

WSCCG Prescribing Data Background Top therapeutic areas Top drugs Inhaled corticosteroids (ICS) Asthma and COPD combined WSCCG data on inhalers Practice data on inhalers

Background: Top therapeutic areas by spend Rank BNF Subparagraph 12-month spend (March 16 – Feb 17) 1 Corticosteroid (respiratory) £3,539,949 2 Control of epilepsy £2,818,893 3 Opioid analgesics £1,672,493

Background: Top drugs by spend Rank Drug 12-month spend (March 16 – Feb 17) 1 Pregabalin £962,268 2 Tiotropium (Spiriva) £820,761 3 Pregabalin (Lyrica) £753,569 4 Beclometasone/formoterol MDI (Fostair) £730,215 5 Insulin Aspart (Novorapid) £697,213 6 Budesonide/formoterol (Symbicort Turbohaler) £544,638

ICS - WSCCG vs National

ICS - spend per 1000 patients (Feb 2017) CCG spending least CCG spending most WSCCG National

ICS - Spend/10,000 patients in practices (Feb 2017)

Inhalers - WSCCG March 16 – Feb 17 Total spend on all inhalers: £4.6m Total spend on COPD inhalers: £1.4m % (by cost) of COPD inhalers ‘in formulary’ varies by practice Average = 66%

Inhalers - Practice Packs ePACT prescribing data, latest 12 months Information on COPD inhalers and all inhalers Tool to promote best practice and improve cost effective prescribing Which inhalers are prescribed at your practice? Is there excessive prescribing of ICS for COPD at your practice? Is there excessive prescribing of bronchodilators at your practice? Are your COPD inhalers in-formulary or off-formulary?